Adrenal Gland Neoplasms Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 18, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Adrenal Gland Neoplasms. It connects disease background, epidemiology, a target-mechanism anchor, clinical competition, transaction activity, unmet need and market attractiveness for portfolio and business-development decisions.

Executive assessment

Adrenal Gland Neoplasms receives a directional strategic score of 59/100. The synthesis combines unmet need (72/100), competitive intensity (96/100, where a higher value means more competition) and market attractiveness (83/100). It is an evidence-organizing framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Tumors or cancer of the ADRENAL GLANDS.

The reproducible entity is Patsnap disease ID 59e1544919e54e1abba9d2272f22acff with MeSH identifier D000310. Entity-level identifiers matter because rare disorders often carry historical names, gene-defined subtypes and overlapping clinical labels. Strategy teams should lock the intended label and synonym set before comparing epidemiology, trials and deals.

A useful target product profile must specify the treatable phenotype, age and severity range, diagnostic confirmation, prior-therapy requirements, treatment setting, acceptable safety profile and endpoint. In Adrenal Gland Neoplasms, an overly broad label can inflate the theoretical market while diluting biological signal and making recruitment less predictable.

The care pathway should be mapped from symptom recognition through specialist referral, molecular or biochemical confirmation, treatment initiation and longitudinal monitoring. Diagnostic delay, fragmented referral and limited centers may be as important commercially as drug efficacy. These barriers should appear explicitly in launch and evidence-generation plans.

Epidemiology and disease burden

Epidemiology signal 1: Brain and Other Central Nervous System Tumor Statistics, 2021

Nonmalignant tumors of the sellar region, particularly pi- tuitary adenomas (also known as pituitary neuroendocrine tumors [PITNET], per current WHO terminology), are the second most common intracranial tumor in adults in the United States after meningioma, accounting for ap- proximately one-­quarter of all nonmalignant brain and other CNS cases in adults (Table 5). Pituitary adenomas may be functional, wherein the tumor causes the pituitary gland to overproduce hormones, or nonfunctional; nonfunctional tu- mors may lead to underproduction of hormones if the tumor is large enough to compress the pituitary stalk and cause the FIGURE 9. Incidence Rates for Specified Malignant Gliomas by Age in Adults Aged ≥20 Years, 2013 to 2017. Rates are limited to Central Brain Tumor Registry of the United States (CBTRUS) definitions for glioma morphology. *These tumors are no longer considered separate from astrocytomas or oligodendrogliomas according to the 2016 World Health Organization central nervous system classification. Data source: CBTRUS data provided by the Centers for Disease Control and Prevention’s National Program of Cancer Registries and the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program, 2013 to 2017 (varying).

Review the underlying epidemiology source

Epidemiology signal 2: 2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes 2016 US Lymphoid Malignancy Statisticsby World Health Organization Subtypes

### Chart Data Transcription Report 1. Basic Chart Information * Chart Title: Lymphoid Neoplasm Incidence Rates* and 2016 Estimated New Cases, United States * Chart Type: Comparative Data Table * Contextual Summary: This table presents the incidence rates and estimated new cases for various lymphoid neoplasm subtypes in the United States, providing detailed epidemiological data for different classifications. 2. Chart Structure and Elements * Axes/Headers: * Row Headers: SUBTYPE * Column Headers: ICD-O-3 CODES, INCIDENCE RATE*, 2011-2012, ESTIMATED NEW CASES, 2016 * Legend/Groups: Not applicable. The table directly lists subtypes and their corresponding data. * Notes and Footnotes: * CNS indicates central nervous system; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein-Barr virus; NK, natural killer cell; NOS, not otherwise specified; T, T cell. * *Rates are per 100,000 and age adjusted to the US standard population. * Subtypes were defined using the World Health Organization (WHO) Classification of Tumours of Haematopoie according to the Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review (CSR), 1975-2012.60 * §: Data not shown due to fewer than 16 cases. 3. Detailed Data Transcription This table provides a comprehensive breakdown of lymphoid neoplasm subtypes, their ICD-O-3 codes, incidence rates per 100,000 population (age-adjusted) for 2011-2012, and estimated new cases for 2016. * 2(a) 2.5.2. Extranodal marginal zone lymphoma: * ICD-O-3 CODES: 9699 (excluding C77.0-77.9) * INCIDENCE RATE*, 2011-2012: 1.1 * ESTIMATED NEW CASES, 2016: 4,450 * 2(a

Review the underlying epidemiology source

Epidemiology signal 3: Cancer Burden in Chinese Older Adults: Insights Into Incidence, Mortality, and Global Comparisons Using GLOBOCAN 2022

Cancer Burden in Chinese Older Adults: Insights Into Incidence, Mortality, and Global Comparisons Using GLOBOCAN 2022 Cancer Burden in Chinese Older Adults: Insights Into Incidence, Mortality, and Global Comparisons Using GLOBOCAN 2022 Yuanjie Zheng1 | He Li2 | Qianru Li1 | Siyi He1 | Yi Teng1 | Mengdi Cao1 | Nuopei Tan1 | Jiachen Wang1 | Tingting Zuo1 | Tianyi Li1 | Wanqing Chen1 1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China | 2Office of National Cancer Regional Medical Centre/Liaoning Hospital of Chinese Academy of Medical Sciences, The First Affiliated Hospital of China Medical University, Shenyang, China Correspondence: Wanqing Chen (chenwq@cicams.ac.cn) Received: 28 September 2024 | Revised: 13 January 2025 | Accepted: 28 May 2025 Funding: This study was supported by Capital's Funds for Health Improvement and Research (Grant No. 2024-­1G-­4023). Keywords: cancer burden | China | epidemiology | GLOBOCAN 2022 | older adults ABSTRACT Objective: To summarize the latest cancer burden among Chinese adults aged 60 years and older and compare it with the global average and four regions classified by Human Development Index (HDI). Methods: Cancer incidence and mortality data were extracted from the GLOBOCAN 2022 database. The estimated numbers of new cases and deaths, age-­standardized incidence rates (ASIRs), and age-­standardized mortality rates (ASMRs) were analyzed for the top ten cancer types in Chinese older adults, categ

Review the underlying epidemiology source

Epidemiology should be converted into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence are not interchangeable; estimates from different age bands, case definitions or health systems should not be pooled without adjustment.

For Adrenal Gland Neoplasms, the next population work should quantify diagnostic yield, severity distribution, referral-center concentration, treatment penetration and survival or progression. Sensitivity analyses should show how each assumption affects recruitment, peak penetration and budget impact. A transparent range is more useful than a single precise-looking estimate built from incompatible sources.

Unmet need and patient-value thesis

The unmet-need thesis must name the failure that a new intervention will change: irreversible progression, incomplete disease control, treatment-limiting toxicity, burdensome administration, weak durability, delayed diagnosis or lack of options for a biomarker-defined subgroup. High disease severity alone does not prove that a clinical program can demonstrate benefit.

A strong Adrenal Gland Neoplasms strategy connects mechanism to a pre-specified responder population and an endpoint understood by regulators, clinicians, patients and payers. It also tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Patient-reported outcomes, functional measures and health-resource use may add value when standard biomarkers do not capture daily burden.

The recommended first development population is the narrowest segment that remains operationally recruitable and has the clearest biological rationale. Expansion should follow evidence of target engagement and response rather than precede it. This sequencing protects capital and improves the interpretability of early clinical results.

Target mechanism anchor: NCC

Electroneutral sodium and chloride ion cotransporter, which acts as a key mediator of sodium and chloride reabsorption in kidney distal convoluted tubules (PubMed:18270262, PubMed:21613606, PubMed:22009145, PubMed:36351028, PubMed:36792826). Also acts as a receptor for the pro-inflammatory cytokine IL18, thereby contributing to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2 (By similarity). May act either independently of IL18R1, or in a complex with IL18R1 (By similarity).

The mechanism anchor for this landscape is SLC12A3. It is a pathway hypothesis, not an assertion that every patient is target-dependent. Translational diligence should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream pathway modulation and a therapeutic window in the intended population.

Critical experiments include orthogonal engagement assays, dose–response work in disease-relevant systems, biomarker qualification, evaluation of compensatory pathways and explicit on-target and off-target safety testing. Human evidence should receive more weight than model-only findings. Negative results in related mechanisms should be analyzed for exposure, population, endpoint and biological lessons.

A go decision requires a chain of evidence: target present in the relevant tissue; modulation achieved at tolerated exposure; pharmacodynamic change observed; and that change plausibly connected to clinical benefit. If any link is missing, the program should remain at a lower investment gate.

Clinical development and competition

The focused query returned 366 registered studies overall. Recent sampled records include:

• NCT07743138 — STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL); status Not yet recruiting; phase Phase 2; sponsor The University of Texas MD Anderson Cancer Center, Summit Therapeutics, Inc.; enrollment 20.
• ChiCTR2600129012 — Clinical Research on the Collection of Biological Samples from Cancer Patients; status Not yet recruiting; phase Not Applicable; sponsor Huzhou Central Hospital; enrollment 100.
• ChiCTR2600128908 — A Retrospective Study on the Safety and Efficacy of One-stage Robot-assisted Laparoscopic Partial Nephrectomy Combined with Ipsilateral Adrenal Tumor Resection; status Not yet recruiting; phase Not Applicable; sponsor The Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University /The First Affiliated Hospital/; enrollment 50.

Trial count is not equivalent to the number of competing products. Observational studies, natural-history cohorts and multiple trials from one asset can distort the headline. Each record should be normalized by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy must compare against the likely standard of care at launch, not only today's treatment. Potential whitespace may come from earlier intervention, genotype selection, improved durability, reduced monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim should be visible in protocol design and prospectively defined analyses.

Recruitment risk deserves its own workstream in Adrenal Gland Neoplasms. Site density, diagnostic testing, competing protocols, travel burden and screen-failure rates should inform country and center selection. Natural-history data can reduce uncertainty but should not substitute for a well-controlled efficacy strategy when endpoints are variable.

Transactions and partnering attractiveness

The search identified 1 recent directly matched transaction records. Representative results:

• Esteve Acquires HRA Pharma Rare Diseases (2024-07-10). Review rights, stage, territory, contingent milestones and disclosed economics before using it as a comparable.

Headline deal value is rarely a clean comparable. Upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope must be separated. A defensible comparable set matches indication, target, modality, stage and territory, then explains every remaining difference.

Partner readiness depends on a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that can retire a material portion of risk.

For Adrenal Gland Neoplasms, direct transaction scarcity can create whitespace, but it can also signal weak validation or a difficult commercial model. Broader pathway deals are useful only when their scientific and economic relevance is made explicit. Avoid treating unrelated rare-disease transactions as interchangeable simply because both populations are small.

Market attractiveness and access

Market attractiveness is shaped by diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, current alternatives, monitoring burden and geographic reimbursement. A rare population can still be attractive when identification is reliable, centers are concentrated and effect size is meaningful; a larger population can disappoint when diagnosis and access are fragmented.

The commercial model should include conservative, base and upside scenarios. Key variables are diagnosed prevalence, eligible share, launch timing, competing approvals, net price, persistence and achievable penetration. Each assumption should have a source, date and range. Scenario outputs should be updated when new epidemiology, trial or transaction evidence arrives.

Payer research should begin before pivotal design so comparator, endpoint and follow-up choices support reimbursement as well as approval. Evidence plans may need quality-of-life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The strongest value proposition ties clinical benefit to outcomes that matter across stakeholders.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate that SLC12A3 is relevant in the selected phenotype.
• Translation risk: connect engagement to a biomarker and clinically meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing capacity and screen-failure assumptions.
• Commercial risk: test access, pricing and adoption with clinicians and payers.
• Data risk: interpret zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are: confirm population and natural history; validate mechanism in human evidence; define a differentiated target product profile; establish early proof of mechanism; and scale only after clinical signal, operational feasibility and commercial logic converge. Every gate needs pre-agreed stop criteria.

Strategic recommendation

Adrenal Gland Neoplasms merits continued, milestone-based evaluation. The opportunity is strongest if a biomarker or phenotype can identify patients with coherent biology, if SLC12A3 modulation is measurable, and if the proposed benefit is meaningful against future care. The current evidence supports further diligence rather than an unconditional investment decision.

The near-term business-development objective is to build a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard provides a common language for comparison, while the attached evidence and explicit gaps preserve analytical traceability.

Methodology and source note

This report was assembled on August 18, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update. Counts are directional search outputs, not clinical, regulatory or investment advice.

Ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Before a transaction or portfolio commitment, rerun searches with synonyms, disease roll-ups, gene or pathway names and asset filters.

Conclusion

The central question for Adrenal Gland Neoplasms is whether a biologically grounded therapy can produce a material patient benefit in an identifiable population and remain differentiated through launch. The current evidence supplies a structured starting point; the gaps define the next diligence plan. Connected MCP searches make the thesis refreshable as disease knowledge, trials and transactions evolve.